Clinical Trials Browser

Breast Neoplasms, Triple Negative Breast Neoplasms

HER2-positive Breast Cancer

Carcinoma, Non-Small-Cell Lung

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Ovarian Neoplasms

Triple Negative Breast Neoplasms

Esophageal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Uterine Cervical Neoplasms, HIV Infections

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Salivary Gland Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Head and Neck Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Breast Neoplasms, Ovarian Neoplasms

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neuroblastoma, Retinoblastoma, Sarcoma, Central Nervous System Neoplasms, Choroid Plexus Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Astrocytoma, Glioblastoma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Head and Neck Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

MK-5890-003

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma

Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer

Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

APX005M

AdvanTIG-211

CRATER

RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC

Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women

CheckMate 9TN

A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

CATHAYA

Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer

CECAVI

HIPEC

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer

Gemcitabine Hydrochloride and Carboplatin With or Without MK-0646 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)

A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy